Helping kids hear the future
Fennec Pharmaceuticals is a late-stage biotechnology company dedicated to improving the lives of children with cancer who experience hearing loss as a result of chemotherapy.
Latest News
- Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients
- Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update
- Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States